Illumina, Inc. $ILMN Stock Sold by Candriam S.C.A.

Candriam S.C.A. trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 58.0% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 58,053 shares of the life sciences company’s stock after selling 80,215 shares during the period. Candriam S.C.A.’s holdings in Illumina were worth $15,946,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Fiduciary Financial Advisors purchased a new stake in Illumina in the second quarter valued at about $26,000. MCF Advisors LLC boosted its holdings in Illumina by 172.4% in the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 100 shares in the last quarter. Keating Financial Advisory Services Inc. purchased a new stake in shares of Illumina during the second quarter worth about $32,000. Rakuten Securities Inc. purchased a new stake in shares of Illumina during the second quarter worth about $33,000. Finally, WealthCollab LLC grew its stake in shares of Illumina by 51.5% during the first quarter. WealthCollab LLC now owns 303 shares of the life sciences company’s stock worth $37,000 after acquiring an additional 103 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Illumina from a “buy” rating to a “hold” rating in a report on Saturday. Barclays upped their price target on shares of Illumina from $160.00 to $200.00 and gave the company an “underweight” rating in a research note on Wednesday, October 7th. Leerink Partners raised their price target on shares of Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a report on Tuesday, September 29th. Weiss Ratings raised shares of Illumina from a “hold (c)” rating to a “buy (b-)” rating in a report on Monday, November 2nd. Finally, Guggenheim lifted their price objective on shares of Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $244.24.

Insider Buying and Selling

In other news, Director Keith Meister sold 50,000 shares of the company’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $227.17, for a total value of $11,358,500.00. Following the sale, the director directly owned 488,917 shares of the company’s stock, valued at $111,067,274.89. This represents a 9.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 1,601,541 shares of company stock worth $354,755,291. Insiders own 2.90% of the company’s stock.

Illumina Trading Up 3.6%

Illumina stock opened at $220.78 on Tuesday. The stock has a 50-day moving average price of $249.25 and a 200 day moving average price of $178.46. The company has a market capitalization of $33.38 billion, a price-to-earnings ratio of 38.00, a price-to-earnings-growth ratio of 3.08 and a beta of 1.46. Illumina, Inc. has a 52 week low of $112.65 and a 52 week high of $309.35. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.26. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The company had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.15 billion. During the same quarter in the prior year, the company earned $1.34 EPS. Illumina’s quarterly revenue was up 4.2% on a year-over-year basis. Sell-side analysts anticipate that Illumina, Inc. will post 5.43 EPS for the current year.

Illumina Company Profile

Illumina, Inc develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data.

The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers internationally.